This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): JNJ-27018966, eluxadoline, MuDelta, Truberzi
Description: This compound is a locally active mu opioid receptor agonist and delta opioid receptor antagonist.
Furiex and Janssen
In November 2009, PPD (now Furiex) entered an agreement with Janssen Pharmaceutica (a Johnson & Johnson company) to develop and commercialize two therapeutic compounds, including this one. Under two agreements, PPD in-licensed the two assets and will advance the compounds through Phase II development. At the completion of Phase II of each compound, Janssen-Cilag will have the option to continue development and commercialization of each compound. In exchange, the Company may receive, for each compound, up to $90.0 million in regulatory milestone payments and up to $75.0 million in sales-based milestone payments, as well as sales-based royalty payments increasing from mid-single digit to low initial double digit percentages as sales volume increase. If Janssen does not buy back a program, PPD will have the option to continue developing and commercializing the compound for that program; and Janssen will receive up to $250 million USD in clinical and sales...See full deal structure in Biomedtracker
Partners: Johnson & Johnson Ironwood Pharmaceuticals, Inc.
Additional information available to subscribers only: